Intellia Therapeutics
NTLA
70 hedge funds and large institutions have $241M invested in Intellia Therapeutics in 2016 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 24 increasing their positions, 15 reducing their positions, and 7 closing their positions.
226% more capital inflows, than outflows
Capital inflows: $88.3M | Capital outflows: $27.1M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
60% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 15
11.47% more ownership
Funds ownership: 39.6% → 51.07% (+11%)
8% more funds holding
Funds holding: 65 → 70 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock Fund Advisors
San Francisco,
California
|
+$7.93M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.48M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.58M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$1.02M |
| 5 |
AG
Artal Group
Luxembourg
|
+$676K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock Advisors
Wilmington,
Delaware
|
-$9.22M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.5M |
| 3 |
EcoR1 Capital
San Francisco,
California
|
-$3.42M |
| 4 |
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$2.32M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$1.41M |
NTLA Hedge Fund Activity: Q4 2016 in Review
70 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q4 2016, worth a combined $241M — down 0.74% from $243M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new NTLA positions and 7 closed out — a net gain of 6 holders — while 24 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $7.93M. The largest seller was BlackRock Advisors, cutting an estimated $9.22M.
- 70 institutional investors held Intellia Therapeutics (NTLA) as of Q4 2016, up from 65 in Q3 2016.
- Funds reported $241M of Intellia Therapeutics stock for Q4 2016, down 0.74% quarter-over-quarter.
- 13 funds opened new Intellia Therapeutics positions in Q4 2016 and 7 closed out, a net change of +6 holders.
- The largest Intellia Therapeutics buyer in Q4 2016 was BlackRock Fund Advisors, an estimated $7.93M added.
- The largest Intellia Therapeutics seller in Q4 2016 was BlackRock Advisors, an estimated $9.22M sold.
Based on aggregated 13F filings for Q4 2016.